semaglutide springfield mo Weightloss Injections Lafayette, LA - Plastic Surgeon | Cosmetic Surgery Evolution Health & Wellness Center

Competitive Position Eli Lilly Market Cap: ~$885-930B 2025 Rev Growth: +40-50% Forward P/E: ~31 Positioning: Market leader, oral GLP-1 coming Novo Nordisk Market Cap: ~$204-215B 2025 Rev Growth: +30% Forward P/E: ~12 Positioning: Struggling with competition, stock down 60% from peak Pfizer Market Cap: ~$160B 2025 Rev Growth: Declining Forward P/E: ~12 Positioning: Lost Metsera bid to competition Key Advantages: Tirzepatide (Mounjaro/Zepbound) consistently outperforms Novo's semaglutide (Ozempic/Wegovy) in head-to-head trials First-mover advantage with oral GLP-1 (orforglipron) Manufacturing scale-up: $12.5B+ invested in new facilities (Virginia, Texas, Puerto Rico) Direct-to-consumer platform (LillyDirect) creating pricing flexibility Valuation & Price Targets Current Price: ~$990 Market Cap: ~$885-930B Valuation Framework 2025 Est

Obesity and impaired metabolic health increase risk of COVID-19-Related mortality in young and middle-aged adults to the level observed in older people: The LEOSS registry

Diabetes Care 45(4):909918

Celebrity has become the credential instant social proof in a market where every company sells the same promise: better health, faster

Eggers test revealed significant publication bias for some outcomes at three months, with no evidence of bias for most outcomes at other time points